Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new study found that using a patient's entire genome helped suggest personalized treatment options for nearly half of children with cancer. The approach led to specific treatment changes in a quarter of these patients and showed promise in treating difficult-to-treat cancers.
The new Northwestern University Center for Cancer Nanotechnology Excellence will use nucleic-acid-based nanoconstructs called Spherical Nucleic Acids (SNAs) to discover new aspects of cancer biology and create effective cancer treatment options. SNAs are nontoxic to humans, offering a versatile tool in medicine.
Researchers at Ohio State University Comprehensive Cancer Center have designed an online database called CanDL to help molecular pathologists identify key cancer gene mutations. The freely accessible database includes information on 60 genes, 334 distinct variants and 169 unique matching literature references across multiple cancers.
Researchers found a core group of genes related to both viral defense and susceptibility to demethylating drug 5-azacytidine. The study suggests that triggering this pathway may improve the effectiveness of immunotherapy drugs in patients with certain types of cancer.
Researchers create economic model to assess life expectancy, management of adverse effects, and quality of life for new oncology drugs like necitumumab. The study finds that the value-based price for necitumumab ranges between $563 and $1,309 per three-week cycle.
A research team has discovered a mechanism to mimic a viral infection in colon cancer stem cells, which could potentially trigger an immune response to fight the disease. Decitabine, a chemotherapy drug, is identified as a potential target to induce viral mimicry and activate an anti-viral response.
A recent study suggests that nitroglycerin could be repurposed as an anti-cancer treatment by improving tumor oxygenation and delivering anticancer drugs. The medication, traditionally used for chest pain, has excellent potential for patient benefit without significant side effects.
Researchers are exploring clinical trials on dogs with naturally occurring cancer to develop new treatments for humans. By studying the genetic basis of canine tumors, scientists hope to gain valuable insights into human cancer treatment.
A recent study published in the Journal of Geriatric Oncology found that 26% of senior oncology patients use complementary or alternative medicines, which can interact with cancer treatments. The study highlights the need for comprehensive screening and documentation of CAM use in older cancer patients.
University of Houston researchers identify liver X receptors as a promising target for developing new pancreatic cancer treatments. The study, led by Chin-Yo Lin, shows that targeting these receptors can slow the growth of tumors and is expected to lead to the development of new drugs.
A new analysis found that patients taking certain heart medications to manage stress may have a longer survival time than those not taking these drugs. Nonselective beta blockers showed the most significant benefit in extending median survival time, particularly among patients with hypertension.
Researchers found that generic heart medications, specifically nonselective beta-blockers, significantly improved overall survival among ovarian cancer patients. This is attributed to the ability of these drugs to block stress pathways involved in tumor growth and spread, with further research needed to explore their potential benefits.
The European Society for Medical Oncology (ESMO) announced the award of its esteemed prizes to three exceptional medical oncologists: Nathan Cherny, Nagahiro Saijo, and Cornelis Punt. These pioneers have made groundbreaking contributions to palliative care integration, medical oncology in Asia, and immunotherapy approaches.
Researchers from MSK Cancer Center announce results from the first published basket study, a clinical trial design that explores drug responses based on specific tumor mutations. The study found preliminary clinical efficacy of vemurafenib in multiple non-melanoma BRAFV600-mutated cancers.
Researchers tested the novel next-generation small molecule drug SGI-110 in MDS and AML patients, revealing it is well-tolerated and biologically active. The study found potent dose-related DNA demethylation associated with clinical response, showing promise for treating leukemia patients.
The ECOG-ACRIN Cancer Research Group has opened the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) phase II precision medicine trial. The trial seeks to enroll approximately 3,000 adults with solid tumors or lymphoma who have returned or worsened after standard therapy.
Researchers from Boston University School of Medicine find no evidence of association between Post Traumatic Stress Disorder (PTSD) and cancer incidence. The large population sample analyzed various cancer diagnoses among people with PTSD compared to the general population, showing no strong associations even among select groups.
Organ transplant recipients are more susceptible to developing regional stage melanoma due to immunosuppressive medications. The study found that transplant patients were four times more likely to be diagnosed with regional stage melanoma and three times more likely to die from the disease.
Researchers discovered that treating tumors with chemotherapy can trigger a response in the immune system, leading to tumor growth. By combining chemotherapy with an immune-blocking drug, they found that this response could be slowed, potentially preventing tumor regrowth.
The Barbara Ann Karmanos Cancer Institute, in partnership with Wayne State University School of Medicine, is one of the lead centers participating in the National Cancer Institute's MATCH Trial. The trial seeks to determine whether targeted therapies for people with tumors having specific gene mutations will be effective.
A new cancer drug candidate, MCB-613, stimulates proteins crucial for tumor growth, causing cell stress and death. It efficiently kills human cancer cells while sparing normal cells, showing promise as a treatment for a range of cancers.
Researchers found that miR-7 directly targets and suppresses the activity of growth factor receptor IGF1R, as well as the pro-oncogenic NF-κB pathway. Increasing miR-7 levels reduced tumor growth in mice and correlated with improved patient survival.
A new algorithm developed by InSilico Medicine has the potential to improve the effectiveness of targeted therapy for cancer patients. The algorithm predicts whether a specific drug will work for an individual patient based on activation of intracellular regulatory pathways.
A LA BioMed researcher is launching a study of medication adherence among dialysis patients, aiming to improve patient health outcomes. The researcher will examine the factors contributing to non-adherence and its impact on cardiovascular disease risk.
Worcester Polytechnic Institute researcher Amity Manning is awarded $747,000 from the National Institutes of Health to explore molecular mechanisms driving genetic instability in cancer cells. The goal is to turn the genetic tables against cancer by understanding how specific molecules affect DNA packaging and organization.
Patients with metastatic prostate cancer who received a two-drug combination of chemotherapy and hormone blocker lived longer than those on hormone-blocker alone, surviving for 57.6 months versus 44 months. The treatment also delayed disease progression by six months.
Researchers at Sanford Burnham Prebys Medical Discovery Institute solved the structure of hypoxia-inducible factors (HIFs), important regulators of tumor response to low oxygen. The findings identify potential targets for new cancer drugs, which could inhibit HIF functions and reduce tumor growth.
Researchers at Duke University have successfully packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness in mice. The new approach delivers the drug directly to tumors while reducing side effects and improving targeting, showing transformative results for patients.
New research published in Science Translational Medicine found that smaller doses of resveratrol are more effective in preventing bowel cancer in mice than high doses. The study showed a 50% reduction in tumour size with lower doses compared to a 25% reduction with higher doses.
A new tool called the Kinase Addiction Ranker (KAR) improves the ability to match drugs to disease by predicting what genetics are truly driving a patient's cancer. The tool clarifies the best drug or combination of drugs that targets specific genetic abnormalities, leading to more effective treatment options.
A study by MIT economists found that pharmaceutical firms tend to invest more in drugs for earlier-stage cancers, resulting in a lack of investment in late-stage cancer treatments. This has resulted in a loss of 890,000 life-years among people diagnosed with cancer in 2003.
Researchers have established the safety and dosing of a new drug for treating blood cancers, targeting dormant cancer stem cells. The drug coaxes these cells to differentiate and exit the bone marrow, where they can be destroyed by chemotherapy agents.
Leading cancer experts recommend several measures to reduce high cancer drug prices, including a post-approval price review mechanism and Medicare negotiations. The recommendations aim to improve patient care and alleviate the financial burden on those affected by high cancer drug costs.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have discovered a new way to improve liver cancer treatment by blocking the activity of the lymphotoxin-beta receptor. The approach, which combines drugs currently in clinical trials with those targeting oncogene signals, may lead to improved patient outcomes.
Mayo researchers found that class II HDAC inhibitors signal through a newly discovered pathway to promote synergy with chemotherapy treatment in anaplastic thyroid cancer. The study identified vorinostat and belinostat as effective agents, which can increase activity of RhoB, a tumor suppressor and stimulate cell death.
Researchers have developed a new drug, CCT245737, that blocks cancer's escape route from chemotherapy, boosting its effectiveness in treating lung and pancreatic cancers. The drug, a CHK1 inhibitor, demonstrates significant anti-cancer activity when combined with chemotherapy in mice.
A major study of over 30,000 women shows that aromatase inhibitors substantially reduce the risk of death from ER-positive breast cancer. Taking aromatase inhibitors for five years reduces the risk of death by 40% compared to tamoxifen.
The Institute for Clinical and Economic Review (ICER) has launched a new program to provide independent analysis on pricing linked to patient benefit for new FDA-approved drugs. The program will produce public reports near the time of FDA approval, providing a transparent basis for price negotiations and coverage decisions.
A new website, the Chemical Probes Portal, aims to guide researchers in selecting better-quality chemical probes, reducing errors and wasting time and money. The platform crowdsources knowledge from leading researchers, providing up-to-date comparative information to help users choose the best probe for their needs.
A national clinical trial involving two effective drug combinations will be compared in a new study. The trial, led by Dr. Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, aims to determine the best sequencing of treatment regimens for patients with melanoma.
Patients with advanced disease experienced significant clinical response after receiving genetically engineered T-cells. The therapy was generally well-tolerated and showed long-term ability to fight tumors.
Researchers at the University of Copenhagen have developed a novel technique to improve glycoprotein-based pharmaceuticals, resulting in better therapeutic effects, longer durations, and faster production. The technology holds considerable potential for improving existing pharmaceuticals and has been published in Nature Biotechnology.
A third of insured breast cancer survivors in Appalachia are not taking critical follow-up treatment, despite having insurance that would cover it. Researchers found that geographical barriers, slower adoption of new technologies, and lack of proper counseling on medication side effects contribute to the issue.
Researchers at Stanford University School of Medicine have developed a database that integrates gene expression patterns of 39 types of cancer with data on patient survival rates. The PRECOG database identifies key pathways and genes associated with poor or good survival outcomes, including FOXM1 and KLRB1.
Researchers found a metabolic imbalance that is oncogenic in diffuse large B-cell lymphomas, characterized by a deficiency of alpha-ketoglutarate. This imbalance disrupts dioxygenase function, leading to various disturbances. The study suggests that metabolic regulation plays a critical role in cancer biology.
Researchers at Oregon State University have developed a system to increase bioavailability of resveratrol and quercetin, potentially allowing extensive use of Adriamycin while reducing cardiac toxicity. The co-administration of these polyphenols enhances the efficacy of cancer drugs by sensitizing cancer cells.
Researchers at University of Hawai'i Cancer Center discover two compounds that effectively stop the growth of brain cancer cells and breast tumors. These targeted treatments are less toxic and could improve quality of life for patients with no effective treatment options besides surgery.
Scientists designed nanoparticles that release chemotherapy drugs paclitaxel in the presence of matrix metalloproteinases (MMPs), which enable cancer metastasis. The system effectively delivers high doses of the drug, halting tumor growth and reducing toxicity.
Researchers developed a new compound that stops B-cell acute lymphoblastic leukemia by locking a disease-related protein in an inactive state. The compound showed promise in animal studies, with improved survival rates and reduced side effects when combined with steroids.
Researchers at the University of Arizona have discovered ethylenedione, a diradical molecule that was previously thought to be elusive. The discovery has significant implications for understanding radical molecular species, industrial processes, and potentially even atmospheric chemistry and climate modeling.
Duke University researchers created a method to enhance tumor-frying nanoparticles with chemotherapeutic coatings, releasing drugs in heated tissue. The technique combines photothermal therapy with localized drug delivery, potentially increasing effectiveness.
New imaging technique using radioactive sodium fluoride allows doctors to visualize unstable calcium deposits in arteries, enabling early diagnosis and development of new medicines. The technique non-invasively detects calcification in atherosclerosis, potentially revolutionizing treatment for patients at risk.
A new Australian study has found a promising drug, PR-104, effective against aggressive T-ALL in laboratory models. The research team is now exploring the molecular biology behind AKR1C3, an enzyme that activates the drug.
Researchers developed a method to optically control microtubule inhibitor drugs with high spatial precision, allowing for targeted treatment of cancer cells. The technique uses blue light to switch on and off the drugs, eliminating systemic side effects and improving therapeutic efficacy.
Researchers at the University of Kentucky have identified a new mechanism for targeting multi-subunit complexes that are critical to viral, bacterial, or cancer function, reducing drug resistance. This approach could lead to more potent drugs with fewer side effects.
Researchers aim to understand how reading interventions impact math skills in children with combined reading and math disabilities. They will use fMRI methods to examine brain activity during reading and math tasks.
Researchers have developed a new cancer drug FY26 that is 49 times more potent than Cisplatin, effectively shutting down the metabolism of cancer cells. The drug works by forcing cancer cells to use their mitochondria, which are defective in healthy cells, leading to cell death.
Researchers at the University of Southern California's Keck Medicine have identified a potential treatment for primary effusion lymphoma, a rare and aggressive form of cancer affecting HIV/AIDS patients. The treatment involves combining FDA-approved immunomodulatory drugs with BRD4 inhibitors, showing promising results in animal models.
Researchers have found a potential treatment option for children with Ewing's sarcoma by combining two active ingredients, Olaparib and Trabectedin, which achieves complete remission in all cases. The combination enhances the sensitivity of cancer cells to these drugs, increasing its effect.
Scientists discover that Methotrexate, commonly used for arthritis, can also treat myeloproliferative neoplasms with fewer side effects and lower costs. This repurposed treatment could revolutionize the care of patients worldwide.